Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Disc Medicine, Inc. Common Stock

IRON

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Last trade $76.53
Day change -$0.06 (-0.08%)
Day range $75.47 – $77.95
Volume 214,705
Market cap $3.49B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.49B
Price / earnings
—
Price / book
5.77×
Price / sales
—
EV / sales
—
EV / EBITDA
-13.03×

Profitability

Earnings per share
-$5.34
Return on assets
-34.75%
Return on equity
-40.23%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.1×
Current ratio
20.3×
Quick ratio
20.3×
Cash ratio
2.62×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$189.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IRON, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$20.08M$18.14M$23.62M$20.75M$17.36M$15.09M$12.18M$9.75M
Research and development$44.08M$46.93M$45.9M$46.22M$50.33M$46.32M$27.76M$24.8M
Total operating expenses$64.16M$65.08M$69.52M$66.97M$67.7M$61.41M$39.95M$34.55M
Operating income-$64.16M-$65.08M-$69.52M-$66.97M-$67.7M-$61.41M-$39.95M-$34.55M
Interest expense-$1.71M-$908K-$844K-$883K-$917K-$910K-$897K-$572K
Income before taxes-$59.43M-$59.46M-$63.45M-$60.44M-$62.22M-$55.2M-$33.97M-$29.28M
Income taxes$109K$69K$51K$88K$102K$52K$119K$176K
Net income-$59.54M-$59.53M-$63.5M-$60.53M-$62.32M-$55.25M-$34.09M-$29.46M
Net income attributable to common shareholders-$59.54M-$59.53M-$63.5M-$60.53M-$62.32M-$55.25M-$34.09M-$29.46M
EBITDA-$64.07M-$64.99M-$69.44M-$66.88M-$67.61M-$61.33M-$39.93M-$34.54M
Basic earnings per share-$1.53-$1.54-$1.65-$1.61-$1.77-$1.58-$1.02-$0.98
Diluted earnings per share-$1.53-$1.54-$1.65-$1.61-$1.77-$1.58-$1.02-$0.98

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

Disc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 6 million shares at $75 per share, generating $450 million in gross proceeds. The company plans to use the funds for research and clinical development of product candidates, including bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and general corporate purposes. The offering is expected to close on October 22, 2026.

GlobeNewswire Inc.

Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine announced it will host a webcast on October 19, 2026 to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. Bitopertin is an investigational oral GlyT1 inhibitor designed to modulate heme biosynthesis and has potential to be the first disease-modifying therapy for erythropoietic porphyrias.

GlobeNewswire Inc.

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. The firm is preparing a class action lawsuit to recover investor losses.

GlobeNewswire Inc.

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, citing uncertainties requiring additional evidence. The stock fell 22% following the announcement. Investors who suffered losses are encouraged to join a prospective class action.

GlobeNewswire Inc.

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter rejecting the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.